IFNα has a distinct disease-modifying effect by acting on MPN Hematopoietic Stem Cells (HSCs) by inducing proliferation through IFNα/β receptor coupled to JAK1 and STAT1-dependent signaling [70]. Here, IFNA2 is linked to myeloproliferative disorder.